CD74 and B-cell non-Hodgkin lymphoma: The anti-CD74 mAb milatuzumab has already been tested in Phase II studies (NCT00868478 and NCT00989586) for the treatment of chronic lymphocytic leukemia and in combination with the anti-CD20 mAb veltuzumab in relapsed and refractory B-cell non-Hodgkin’s lymphoma.